Longboard Pharmaceuticals Inc

Longboard Pharmaceuticals — Investor Presentation (December 2022)

24 slides from Longboard Pharmaceuticals's investor presentation, Dec 5, 2022

  1. Slide 1: Corporate Presentation - The Potential of LP352

    Corporate Presentation - The Potential of LP352 December 2022 CONFIDENTIAL Exhibit 99.1

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements This presentation contains forward-looking statements about Longboard Pharmaceuticals, Inc. (“we,” “Longboard” or the “Company”), including statements regarding: our future results of operations and financial position; business strategy; the timing, costs, conduct and resu

  3. Slide 3: Longboard's Pipeline of Next Generation GPCR Programs

    Longboard’s Pipeline of Next Generation GPCR Programs LONGBOARD PHARMACEUTICALS Program MOA Therapeutic Area Preclinical Ph I Ph II Ph III Anticipated Milestones LP352 5-HT2C Superagonist DEEs and other refractory epilepsies Ph 1 data at medical mtg. - H1 2022 Ph 1 CSF PK/PD qEEG data - Q4 2022 Ph 1

  4. Slide 4: LP352 has the Potential to Make a Difference Across a Range of DEEs

    LP352 has the Potential to Make a Difference Across a Range of DEEs LONGBOARD PHARMACEUTICALS Penetrates the brain in a dose-dependent, consistent and sustained manner LP352 Greater Selectivity and Specificity The product of 20 years of world-class GPCR research and optimization Demonstrated consist

  5. Slide 5: The Potential of 5-HT2C Superagonist LP352

    The Potential of 5-HT2C Superagonist LP352 A potential best-in-class serotonin receptor agonist anti-seizure product candidate that is designed to be highly selective and being dose-optimized to treat a broad range of DEEs effectively and safely CONFIDENTIAL

  6. Slide 6: The Potential of LP352

    The Potential of LP352 LONGBOARD PHARMACEUTICALS Greater Selectivity and Specificity Preclinical Validation Clinical Validation SAD/MAD Clinical Validation CSF/EEG ** 5-HT2 agonist designed to only bind to the 5-HT2C receptor* 5-HT2 agonist that has no detected activity at receptors associated with

  7. Slide 7: 5-HT2 Evolution in Rare Epilepsies

    LONGBOARD PHARMACEUTICALS 5-HT2 Evolution in Rare Epilepsies Weight Loss Drugs Repurposed Designed for Weight Loss Compound: FINTEPLA® DS (fenfluramine, ZX008) Lorcaserin (Marketed as BELVIQ) History: Approved for weight loss in 1973, became popular in 1990s in Fen-Phen (never approved in combo) Wit

  8. Slide 8: LP352 Designed to be a Next Generation 5-HT2C with Greater Selectivity and Specificity

    LP352 Designed to be a Next Generation 5-HT2C with Greater Selectivity and Specificity LONGBOARD PHARMACEUTICALS Serotonin Receptor Subtype EC50, nM Ki, nM Selectivity 5-HT2C vs 5-HT2B Selectivity 5-HT2C vs 5-HT2A Potential Adverse Events Per Receptor Subtype LP352 5-HT2C Superagonist 5-HT2C ~120 ~5

  9. Slide 9: LP352 Inhibited Seizure Activity in Multiple Preclinical Models

    LP352 Inhibited Seizure Activity in Multiple Preclinical Models LONGBOARD PHARMACEUTICALS Corneal Kindling Pentylenetetrazol (PTZ) (i.v.) Scn1aA1783V/WT Transgene scn1lab Transgene Ethyl ketopentenoate (EKP) Kainic acid (KA) Model Partial (focal) limbic seizures Acute seizure Genetic model of Dravet

  10. Slide 10: LP352 Significantly Reduced Epileptiform Frequency & Duration in Zebrafish scn1lab Model

    LONGBOARD PHARMACEUTICALS Wild-type scn -/- scn -/- LP352 * * 6 4 2 0 * DURATION OF EPILEPTIFORM ACTIVITY FREQUENCY OF EPILEPTIFORM EVENTS LP352 Significantly Reduced Epileptiform Frequency & Duration in the Zebrafish scn1lab Model of Dravet Syndrome LP352 demonstrated 85% reduction of epileptiform

  11. Slide 11: LP352 Significantly Improved Seizure Activity in the Zebrafish EKP Epilepsy Model

    LONGBOARD PHARMACEUTICALS LP352 Significantly Improved Seizure Activity in the Zebrafish EKP Epilepsy Model N=18-20/group, **p < 0.0001 Definitions: LFP = local field potential; EKP= Ethyl ketopentenoate; Veh = Vehicle LP352 demonstrated ~69% reduction in seizure activity Epileptiform brain activity

  12. Slide 12: LP352 Significantly Reduced Seizure Activity in the Zebrafish Kainic Acid Epilepsy Model

    LONGBOARD PHARMACEUTICALS LP352 Significantly Reduced Seizure Activity in the Zebrafish Kainic Acid Epilepsy Model N=12-14/group Definitions: KA= Kainic Acid; Veh = Vehicle LP352 demonstrated ~82% reduction of seizure activity LP352 Normalized Power Spectral Density CONFIDENTIAL **p < 0.01 **p < 0.0

  13. Slide 13: LP352 Demonstrated Dose-Dependent Improvement in Time to Clonic Seizures in PTZ Mouse Model

    LP352 Demonstrated Dose-Dependent Improvement in Time to Clonic Seizures in PTZ Mouse Model LONGBOARD PHARMACEUTICALS Effect of LP352 on the Threshold for Seizures Induced by the Timed Intravenous Infusion of PTZ in Male Mice Compound Animal Weight (Grams, Mean ± S.E.M.) Time of Test PTZ Dose (mg/kg

  14. Slide 14: LP352 Ph 1 Multiple Ascending Dose (MAD) Results

    LONGBOARD PHARMACEUTICALS LP352 Ph 1 Multiple Ascending Dose (MAD) Results Favorable Safety & Tolerability Results Observed Majority of AEs were mild to moderate (most common was headache) AEs generally consistent with expected CNS effects and expected effects of serotonergic drugs At the maximum pl

  15. Slide 15: LP352 Ph 1 Single Ascending Dose (SAD) Results

    LP352 Ph 1 Single Ascending Dose (SAD) Results Favorable Pharmacokinetics and Pharmacodynamics Results Observed LONGBOARD PHARMACEUTICALS Single Ascending Dose & Single-Dose Food Effect (N=40) Percent Change from Baseline in 2-Hour Prolactin Concentration Across All Dose Groups Under Fasted Conditio

  16. Slide 16: LP352 Ph 1 MAD Results: Pharmacokinetics and Pharmacodynamics

    LP352 Ph 1 MAD Results Favorable Pharmacokinetics and Pharmacodynamics Results Observed LONGBOARD PHARMACEUTICALS Multiple Ascending Dose & Dose Titration (N=43) Key Summary of LP352 Pharmacokinetic Parameters by Cohort (Day 14) - MAD and Dose Titration (PK Analysis Population) Parameter (Unit) MAD

  17. Slide 17: LP352 102: A Phase 1 PK/PD CNS Study in Adult Healthy Volunteers

    Cohort 1 (n=10) 6 mg TID 28 Days Day 25 Screening Daily Dosing of Liquid Formulation Follow-up Days 3-11 (target treatment) A Phase 1, Open-label Study to Assess Central Nervous System Pharmacokinetics (PK) and Pharmacodynamics (PD) of Orally Administered LP352 Key Study Objectives: Characterize the

  18. Slide 18: Steady State Plasma & CSF Concentrations for LP352

    Steady State Plasma & CSF Concentrations for LP352 (6mg & 12mg) 12 mg TID Exceeded Ki Value for 5-HT2C Activity throughout Dosing Interval* LONGBOARD PHARMACEUTICALS *Topline data from 102 study Ki LP352 Concentration (ng/mL) LP352 Concentration (ng/mL) Time (hrs) Time (hrs) Ki CONFIDENTIAL The vast

  19. Slide 19: Cmax and AUC CSF vs. Plasma Correlations

    Cmax and AUC CSF vs. Plasma Correlations Strong Correlation Between Plasma and CSF PK Parameters* LONGBOARD PHARMACEUTICALS *Topline data from 102 study R2 = 0.89 R2 = 0.97 CSF vs. LP352 Cmax CSF vs. LP352 AUCtau Cmax of LP352 in CSF (ng/mL) AUCtau of LP352 in CSF (hr*ng/mL) Cmax of LP352 in Plasma

  20. Slide 20: 5-Minute Resting qEEG Spectral Amplitudes (Days -1, 1 and 3)

    5-Minute Resting qEEG Spectral Amplitudes in Clinical Frequency Bands (Days -1,1 and 3) LP352 Demonstrated Early qEEG Changes* *Topline data from 102 study Small and large salient contrasts (≥10%, ≥15%) are indicated by light and heavy arrows (blue=decrease, red=increase) respectively. Small and lar

  21. Slide 21: 5-Minute Resting qEEG Spectral Amplitudes (Days 10 and 16)

    5-Minute Resting qEEG Spectral Amplitudes in Clinical Frequency Bands (Days 10 and 16) LP352 Demonstrated Sustained Effects on qEEG Activity After Continuous Dosing in a Dose-Dependent Manner, Thus Indicating Receptor Engagement* LONGBOARD PHARMACEUTICALS *Topline data from 102 study ** On Day 16, a

  22. Slide 22: LP352-102 Phase 1 Study: Key Takeaways To Date

    LP352-102 Phase 1 Study: Key Takeaways To Date First known study of its kind for a 5HT2 agonist (e.g. fenfluramine or lorcaserin) Favorable safety and tolerability results observed, with AEs generally consistent with previous clinical studies Plasma and CSF PK concentration increased in a dose-depen

  23. Slide 23: PACIFIC Study Design

    6 mg 9 mg 12 mg Participant remains on 6, 9 or 12 mg based on tolerability during up-titration Placebo (n=10) LP352 (n=40) 5 Wks 30 Days Screening Period Randomization & Up-Titration Maintenance* Down-Titration Follow-up Period Days 1-15 Days 16-75 Days 76-80/90** Key Inclusion Criteria: Development

  24. Slide 24: Thank you!

    Thank you! Nasdaq: LBPH CONFIDENTIAL

Longboard Pharmaceuticals — Investor Presentation (December 2022) on 6ix